Corbus Pharmaceuticals Holdings Inc. (CRBP)
Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss
Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss
📈 **POSITIVE** • Low confidence analysis (47%) • Moderate positive clinical data • Good growth prospects **Sentiment:** Positive (55%) **Content type:** Clinical